Inhibiting Mutant FGFR2 In Endometrial Cancer By Extracellular Blockade
Funder
National Health and Medical Research Council
Funding Amount
$354,859.00
Summary
Endometrial cancer is a common gynecological cancer in women and new therapies are required to improve survival rates. We have identified mutations in a key cell membrane protein (FGFR2) and shown that endometrial cancer cells with these mutations have altered growth factor dependence. Inhibiting these mutant proteins can result in cell death. By characterizing these mutations and their cellular effects we will be able to develop specific blocking agents for use as potential novel treatments